文献速递垂体与肾上腺疾病

肢端肥大症与原发性恶性肿瘤发病率增加相关:瑞典全国研究数据

Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden.
PubMed 文献 · J Clin Endocrinol Metab · 2026-01-01

癌症死亡仅在40至60岁患者中显著升高,生化控制对癌症发生影响较小。

要点

  • 肢端肥大症患者全癌发生风险校正HR为1.28(95%CI 1.11-1.49)。
  • 结直肠癌、肺癌、血液系统癌及女性乳腺癌风险均显著升高。
  • 生化控制对癌症发生影响较小,提示风险可能不限于GH过度分泌。

核心结论

  • 瑞典全国匹配队列研究显示肢端肥大症患者癌症发生风险增加,诊断后需警惕癌症早期征象。
  • 生化控制对癌症发生增加影响较小,提示存在GH过度分泌之外的作用机制。

研究设计与样本

  • 癌症诊断和死亡数据来自瑞典垂体登记和国家患者登记,采用Cox比例风险回归模型校正年龄、性别和合并症。

主要发现

  • 全癌校正HR为1.28(95%CI 1.11-1.49),结直肠癌1.84(1.28-2.64),肺癌1.95(1.22-3.11),血液系统癌1.68(1.03-2.73),女性乳腺癌1.46(1.02-2.11),均从肢端肥大症诊断前5年起计算。
  • 诊断后第二癌症有增加趋势,校正HR为1.54(95%CI 0.98-2.44)。
  • 癌症死亡仅在40至60岁患者中显著升高,校正HR为1.48(95%CI 1.19-1.85)。
  • IGF-1持续升高患者总体死亡率较高(HR 1.50,95%CI 1.10-2.01),但与生化控制患者相比癌症发生率或癌症相关死亡率无增加。

临床怎么用

  • 对肢端肥大症患者应保持警惕,关注癌症早期征象,尤其是在诊断后。
  • 生化控制可能不足以完全消除癌症风险,需综合考虑其他机制。

局限性

  • 原文未明确报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: GH excess and elevated IGF-1 in acromegaly are considered to promote cancer development. OBJECTIVE: To investigate cancer incidence and outcome in patients with acromegaly in relation to biochemical control. METHODS: Matched cohort study in patients with acromegaly diagnosed from 1991 to 2018 and 10 controls per case from the Swedish population. Cancer diagnoses and fatalities were obtained from the Swedish Pituitary and National Patient Registers. Adjusted hazard ratio (HR) and 95% confidence intervals (CIs) for cancer incidence and death were estimated using a Cox proportional hazard regression model adjusted for age, sex, and comorbidity. RESULTS: We included 1035 patients with acromegaly (49.5% female; median age 52.0 years) and 10 261 matched controls. Patients had higher adjusted HR (95% CI) for all cancer (1.28, 1.11-1.49), colorectal cancer (1.84, 1.28-2.64), lung cancer (1.95, 1.22-3.11), hematologic cancer (1.68, 1.03-2.73), and breast cancer in women (1.46, 1.02-2.11) from 5 years before acromegaly diagnosis. Second cancers after diagnosis tended to be increased (1.54, 0.98-2.44). Death from cancer was only significantly elevated in patients 40 to 60 years of age (1.48, 1.19-1.85). Patients with persistently elevated IGF-1 had a higher overall mortality rate (1.50, 1.10-2.01) but no increase in cancer incidence or cancer-related mortality compared to biochemically controlled patients. CONCLUSION: This nationwide, matched cohort study showed an increased risk of cancer in patients with acromegaly, underscoring the importance of vigilance for early signs of cancer after acromegaly diagnosis. Biochemical control had minor effects on increased cancer development, indicating an effect beyond GH hypersecretion.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Tsatsaris E, Robèrt J, Burman P, et al. Acromegaly is associated with an increased incidence of primary malignant tumors: data from a national study in Sweden. J Clin Endocrinol Metab. 2026. PMID: 41913644. doi:10.1210/clinem/dgag137

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。